- Home
- CABA vs ONCH Comparison
CABA vs ONCH Comparison
Compare CABA & ONCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CABA | ONCH |
|---|---|---|
| Founded | 2017 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.7M | 223.4M |
| IPO Year | 2019 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CABA | ONCH |
|---|---|---|
| Price | $2.16 | $10.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $14.57 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 33.5K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $10.16 |
| 52 Week High | $3.67 | $10.63 |
Technical Indicators
Market Signals| Indicator | CABA | ONCH |
|---|---|---|
| Relative Strength Index (RSI) | 44.96 | N/A |
| Support Level | $2.08 | N/A |
| Resistance Level | $2.25 | N/A |
| Average True Range (ATR) | 0.13 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 40.79 | 0.00 |
Price Performance
Historical ComparisonAbout CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
About ONCH 1RT Acquisition Corp. Class A Ordinary Share
1RT Acquisition Corp is a blank check company.